Patient´s own immune cells instead of industrial drugs: piTheraπ
iREM (Immunological Re-Education of Malignancy): An example of personal Immunotherapy (piTheraπ) in CANCER
Our immune system – individual and unique like a fingerprint – is designed to serve the needs of one’s own organism. If we want to take advantage of it in the treatment of various diseases, this can only be done on the basis of a unique, personal immunotherapy.
A life in health is unimaginable without a well functioning immune system. In case it doesn´t work adequately in just one single detail, this will affect a person’s state of health sustainably – as the example of AIDS shows. Hence, the immune system is the most effective guarantor of our health, but still sometimes fails in its protective service, e. g. when encountering sudden mutations (cancer) or unknown molecules (autoimmune phenomena or allergies)
Treatments with intention of symptom-relieving do not help sick people much. If properly instructed, our immune system will still fight any disorders most effectively: Under laboratory conditions it could be demonstrated that immune cells (or their products) – if primed correctly – display piTheraπ´s effect with amaizing success in various diseases such as bronchial asthma, chronic viral infection e. g. genital warts , and even in CANCER.
It is known that immune and cancer cells are genetically almost identical, i. e. some sort of “siblings”. If one of these siblings gets off the right path (cancer!), its counterpart will rather try to bring him back on track instead of attacking or destroying. Our experiments in the lab and clinical observations support this notion. We subsume this phenomenon for cancer treatment under the term iREM (Immunological Re-Education of Malignancy):
In contrast to commonly applied destructive methods (e.g. chemotherapy, etc.), iREM follows an alternative way by transforming malignant tumor cells into benign ones by means of immunological instruction. In the course of a natural aging process, the „transformed“ tumor cells gradually die. And although a tumor residue may still be conceivable right after completing the treatment, this is to be considered as harmless tissue only.
Which patients may benefit from iREM?
A number of criteria are decisive for a successful treatment: Age, vitality, mobility, tumor load (amount), a reasonable life expectancy – and as little chemotherapy as possible: Such pre-treatment may result in various tumor mutations, which means that tumor cells may alter their characteristics or immunogenicity. In addition, iREM-trained immune cells are likely to be destroyed by cytostatic agents immediately upon re-injection. This, indeed, would probably undermine the expected success of iREM. Therefore, the best chances of curing are probably for “virgin”, i. e. not aggressively treated patients and not the terminal stage of cancer diseases, respectively.